FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004182170> ?p ?o ?g. }

• W2004182170 endingPage "346" @default.
• W2004182170 startingPage "338" @default.
• W2004182170 abstract "Purpose/Objective(s) To evaluate the obliteration rate and potential adverse effects of single-fraction proton beam stereotactic radiosurgery (PSRS) in patients with cerebral arteriovenous malformations (AVMs). Methods and Materials From 1991 to 2010, 248 consecutive patients with 254 cerebral AVMs received single-fraction PSRS at our institution. The median AVM nidus volume was 3.5 cc (range, 0.1-28.1 cc), 23% of AVMs were in critical/deep locations (basal ganglia, thalamus, or brainstem), and the most common prescription dose was 15 Gy(relative biological effectiveness [RBE]). Univariable and multivariable analyses were performed to assess factors associated with obliteration and hemorrhage. Results At a median follow-up time of 35 months (range, 6-198 months), 64.6% of AVMs were obliterated. The median time to total obliteration was 31 months (range, 6-127 months), and the 5-year and 10-year cumulative incidence of total obliteration was 70% and 91%, respectively. On univariable analysis, smaller target volume (hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.86-0.93, P<.0001), smaller treatment volume (HR 0.93, 95% CI 0.90-0.96, P<.0001), higher prescription dose (HR 1.16, 95% CI 1.07-1.26, P=.001), and higher maximum dose (HR 1.14, 95% CI 1.05-1.23, P=.002) were associated with total obliteration. Deep/critical location was also associated with decreased likelihood of obliteration (HR 0.68, 95% CI 0.47-0.98, P=.04). On multivariable analysis, critical location (adjusted HR [AHR] 0.42, 95% CI 0.27-0.65, P<.001) and smaller target volume (AHR 0.81, 95% CI 0.68-0.97, P=.02) remained associated with total obliteration. Posttreatment hemorrhage occurred in 13 cases (5-year cumulative incidence of 7%), all among patients with less than total obliteration, and 3 of these events were fatal. The most common complication was seizure, controlled with medications, both acutely (8%) and in the long term (9.1%). Conclusions The current series is the largest modern series of PSRS for cerebral AVMs. PSRS can achieve a high obliteration rate with minimal morbidity. Post-treatment hemorrhage remains a potentially fatal risk among patients who have not yet responded to treatment. To evaluate the obliteration rate and potential adverse effects of single-fraction proton beam stereotactic radiosurgery (PSRS) in patients with cerebral arteriovenous malformations (AVMs). From 1991 to 2010, 248 consecutive patients with 254 cerebral AVMs received single-fraction PSRS at our institution. The median AVM nidus volume was 3.5 cc (range, 0.1-28.1 cc), 23% of AVMs were in critical/deep locations (basal ganglia, thalamus, or brainstem), and the most common prescription dose was 15 Gy(relative biological effectiveness [RBE]). Univariable and multivariable analyses were performed to assess factors associated with obliteration and hemorrhage. At a median follow-up time of 35 months (range, 6-198 months), 64.6% of AVMs were obliterated. The median time to total obliteration was 31 months (range, 6-127 months), and the 5-year and 10-year cumulative incidence of total obliteration was 70% and 91%, respectively. On univariable analysis, smaller target volume (hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.86-0.93, P<.0001), smaller treatment volume (HR 0.93, 95% CI 0.90-0.96, P<.0001), higher prescription dose (HR 1.16, 95% CI 1.07-1.26, P=.001), and higher maximum dose (HR 1.14, 95% CI 1.05-1.23, P=.002) were associated with total obliteration. Deep/critical location was also associated with decreased likelihood of obliteration (HR 0.68, 95% CI 0.47-0.98, P=.04). On multivariable analysis, critical location (adjusted HR [AHR] 0.42, 95% CI 0.27-0.65, P<.001) and smaller target volume (AHR 0.81, 95% CI 0.68-0.97, P=.02) remained associated with total obliteration. Posttreatment hemorrhage occurred in 13 cases (5-year cumulative incidence of 7%), all among patients with less than total obliteration, and 3 of these events were fatal. The most common complication was seizure, controlled with medications, both acutely (8%) and in the long term (9.1%). The current series is the largest modern series of PSRS for cerebral AVMs. PSRS can achieve a high obliteration rate with minimal morbidity. Post-treatment hemorrhage remains a potentially fatal risk among patients who have not yet responded to treatment." @default.
• W2004182170 created "2016-06-24" @default.
• W2004182170 creator A5001528733 @default.
• W2004182170 creator A5006359971 @default.
• W2004182170 creator A5008003566 @default.
• W2004182170 creator A5017047283 @default.
• W2004182170 creator A5019793262 @default.
• W2004182170 creator A5023808346 @default.
• W2004182170 creator A5028403057 @default.
• W2004182170 creator A5033847023 @default.
• W2004182170 creator A5044232944 @default.
• W2004182170 creator A5045425111 @default.
• W2004182170 date "2014-06-01" @default.
• W2004182170 modified "2023-10-14" @default.
• W2004182170 title "Single-Fraction Proton Beam Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations" @default.
• W2004182170 cites W1488971511 @default.
• W2004182170 cites W1622706284 @default.
• W2004182170 cites W1924985078 @default.
• W2004182170 cites W1963567408 @default.
• W2004182170 cites W1978002281 @default.
• W2004182170 cites W1990700901 @default.
• W2004182170 cites W2001751572 @default.
• W2004182170 cites W2007302470 @default.
• W2004182170 cites W2017142224 @default.
• W2004182170 cites W2029901523 @default.
• W2004182170 cites W2037803738 @default.
• W2004182170 cites W2041578551 @default.
• W2004182170 cites W2041876348 @default.
• W2004182170 cites W2053167738 @default.
• W2004182170 cites W2054474589 @default.
• W2004182170 cites W2059142743 @default.
• W2004182170 cites W2072636222 @default.
• W2004182170 cites W2075581846 @default.
• W2004182170 cites W2075834798 @default.
• W2004182170 cites W2083260250 @default.
• W2004182170 cites W2083549164 @default.
• W2004182170 cites W2089702044 @default.
• W2004182170 cites W2097545213 @default.
• W2004182170 cites W2102918890 @default.
• W2004182170 cites W2141001988 @default.
• W2004182170 cites W2151055856 @default.
• W2004182170 cites W2155371608 @default.
• W2004182170 cites W2161820349 @default.
• W2004182170 cites W2326209559 @default.
• W2004182170 cites W3026529836 @default.
• W2004182170 doi "https://doi.org/10.1016/j.ijrobp.2014.02.030" @default.
• W2004182170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34701860" @default.
• W2004182170 hasPublicationYear "2014" @default.
• W2004182170 type Work @default.
• W2004182170 sameAs 2004182170 @default.
• W2004182170 citedByCount "33" @default.
• W2004182170 countsByYear W20041821702014 @default.
• W2004182170 countsByYear W20041821702015 @default.
• W2004182170 countsByYear W20041821702016 @default.
• W2004182170 countsByYear W20041821702017 @default.
• W2004182170 countsByYear W20041821702018 @default.
• W2004182170 countsByYear W20041821702019 @default.
• W2004182170 countsByYear W20041821702020 @default.
• W2004182170 countsByYear W20041821702021 @default.
• W2004182170 countsByYear W20041821702022 @default.
• W2004182170 countsByYear W20041821702023 @default.
• W2004182170 crossrefType "journal-article" @default.
• W2004182170 hasAuthorship W2004182170A5001528733 @default.
• W2004182170 hasAuthorship W2004182170A5006359971 @default.
• W2004182170 hasAuthorship W2004182170A5008003566 @default.
• W2004182170 hasAuthorship W2004182170A5017047283 @default.
• W2004182170 hasAuthorship W2004182170A5019793262 @default.
• W2004182170 hasAuthorship W2004182170A5023808346 @default.
• W2004182170 hasAuthorship W2004182170A5028403057 @default.
• W2004182170 hasAuthorship W2004182170A5033847023 @default.
• W2004182170 hasAuthorship W2004182170A5044232944 @default.
• W2004182170 hasAuthorship W2004182170A5045425111 @default.
• W2004182170 hasConcept C120665830 @default.
• W2004182170 hasConcept C121332964 @default.
• W2004182170 hasConcept C126322002 @default.
• W2004182170 hasConcept C141071460 @default.
• W2004182170 hasConcept C207103383 @default.
• W2004182170 hasConcept C2779603958 @default.
• W2004182170 hasConcept C2780387249 @default.
• W2004182170 hasConcept C2989005 @default.
• W2004182170 hasConcept C44249647 @default.
• W2004182170 hasConcept C509974204 @default.
• W2004182170 hasConcept C61511704 @default.
• W2004182170 hasConcept C71924100 @default.
• W2004182170 hasConceptScore W2004182170C120665830 @default.
• W2004182170 hasConceptScore W2004182170C121332964 @default.
• W2004182170 hasConceptScore W2004182170C126322002 @default.
• W2004182170 hasConceptScore W2004182170C141071460 @default.
• W2004182170 hasConceptScore W2004182170C207103383 @default.
• W2004182170 hasConceptScore W2004182170C2779603958 @default.
• W2004182170 hasConceptScore W2004182170C2780387249 @default.
• W2004182170 hasConceptScore W2004182170C2989005 @default.
• W2004182170 hasConceptScore W2004182170C44249647 @default.
• W2004182170 hasConceptScore W2004182170C509974204 @default.
• W2004182170 hasConceptScore W2004182170C61511704 @default.
• W2004182170 hasConceptScore W2004182170C71924100 @default.
• W2004182170 hasIssue "2" @default.
• W2004182170 hasLocation W20041821701 @default.

• next